UPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level-of-evidence-1 studies

Breast Cancer Research

Volumn 16, Issue 4, 2014, Pages

  Duffy, Michael J ^a,b   McGowan, Patricia M ^a,b   Harbeck, Nadia ^c   Thomssen, Christoph ^d   Schmitt, Manfred ^e  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Department of Gynecology Universitaetsklinikum Halle ^*  (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER PROGNOSIS; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; ENZYME BLOOD LEVEL; HUMAN; LABORATORY TEST; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VALIDATION PROCESS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROGNOSIS; REPRODUCIBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; REPRODUCIBILITY OF RESULTS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84910070390     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0428-4     Document Type: Review

References (99)

1. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Lafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011, 9:S1-S32.
2. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. Sci Transl Med 2013, 5:196cm6. 10.1126/scitranslmed.3005950, 23903752.
3. Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006, 43:325-347. 10.1080/10408360600739218, 16769596.
4. Hurvitz SA, Hu Y, O'Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2013, 39:219-229. 10.1016/j.ctrv.2012.04.008, 3835685, 22658319.
5. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88:1456-1466. 10.1093/jnci/88.20.1456, 8841020.
6. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446-1452. 10.1093/jnci/djp335, 2782246, 19815849.
7. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001, 93:913-992. 10.1093/jnci/93.12.913, 11416112.
8. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, et al. Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94:116-128. 10.1093/jnci/94.2.116, 11792750.
9. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C. Ten-year analysis of the prospective multicenter Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013, 49:1825-1835. 10.1016/j.ejca.2013.01.007, 23490655.
10. Duffy MJ. The urokinase plasminogen activation system: role in malignancy. Curr Pharm Des 2004, 10:39-49. 10.2174/1381612043453559, 14754404.
11. Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011, 11:617-634. 10.1586/erm.11.47, 21745015.
12. Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des 2011, 17:1944-1961. 10.2174/138161211796718143, 21711235.
13. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J. Plasminogen activation and cancer. Thromb Haemost 2005, 93:676-681.
14. MEROPS - the Peptidase Database. http://merops.sanger.ac.uk/cgi-bin/speccards?sp=sp001823;type=peptidase
15. Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010, 10:1051-1067. 10.1586/erm.10.71, 21080821.
16. Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol 2012, 5:64259.
17. Tjwa M, Moura R, Moons L, Plaisance S, De Mol M, Jansen S, Dewerchin M, Verfaillie C, Carmeliet P. Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation. J Cell Mol Med 2009, 13:4587-4595. 10.1111/j.1582-4934.2008.00521.x, 19210287.
18. Beaufort N, Plaza K, Utzschneider D, Schwarz A, Burkhart JM, Creutzburg S, Debela M, Schmitt M, Ries C, Magdolen V. Interdependence of kallikrein-related peptidases in proteolytic networks. Biol Chem 2010, 391:581-587. 10.1515/bc.2010.055, 20302517.
19. Ferraris GM, Sidenius N. Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. Semin Thromb Hemost 2013, 39:347-355. 10.1055/s-0033-1334485, 23532573.
20. Jo M, Thomas KS, Marozkina N, Amin TJ, Silva CM, Parsons SJ, Gonias SL. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 2005, 280:17449-17457. 10.1074/jbc.M413141200, 15728176.
21. Kiyan J, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J 2005, 24:1787-1797. 10.1038/sj.emboj.7600669, 1142599, 15889147.
22. Montuori N, Cosimato V, Rinaldi L, Rea VE, Alfano D, Ragno P. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost 2013, 109:309-318. 10.1160/TH12-08-0546, 23238745.
23. Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, Blasi F. Alpha-2 macroglobulin receptor/Ldl receptor-related protein (Lrp)-dependent internalization of the urokinase receptor. J Cell Biol 1995, 131:1609-1622. 10.1083/jcb.131.6.1609, 2120674, 8522616.
24. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009, 14:4575-4587.
25. Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 2008, 175:33-39.
26. Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, Andreasen PA. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009, 14:1337-1361.
27. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997, 16:2610-2620. 10.1093/emboj/16.10.2610, 1169872, 9184208.
28. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmbäck K, Drew AF, Flick MJ, Witte DP, Danø K, Degen JL. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998, 16:3097-3104. 10.1038/sj.onc.1201869, 9671388.
29. Almholt K, Lund LR, Rygaard J, Nielsen BS, Danø K, Rømer J, Johnsen M. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2004, 113:525-532.
30. Ossowski L. Antibodies to plasminogen activator inhibits human tumor metastasis. Cell 1983, 35:611-619. 10.1016/0092-8674(83)90093-4, 6418388.
31. Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, Botkjaer KA, Andreasen PA, Quigley JP. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. Neoplasia 2011, 13:806-821. 3182273, 21969814.
32. Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol Cancer Ther 2013, 12:2378-2388. 10.1158/1535-7163.MCT-13-0041, 23990114.
33. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med 1998, 4:923-928. 10.1038/nm0898-923, 9701244.
34. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A. Host-derived plasminogen activator-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004, 23:6986-6990. 10.1038/sj.onc.1207859, 15286708.
35. Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A, DeClerck YA. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 2001, 61:5587-5594.
36. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000, 82:1702-1708. 10.1054/bjoc.2000.1207, 2374508, 10817507.
37. Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst 2012, 104:1470-84. 10.1093/jnci/djs377, 3529616, 22984202.
38. Schmitt M, Harbeck N, Daidone MG, Brynner N, Duffy MJ, Foekens JA, Sweep FC. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol 2004, 25:1397-406.
39. Daidone MG, Foekens JA, Harbeck N, Martens J, Brunner N, Thomssen C, Hall JA, Salgado R, Dittmer J, Geurts-Moespot A, Duffy MJ, Sweep CG, Schmitt M. Identification, validation and clinical implementation of tumor-associated biomarkers: translational strategies of the EORTC - Pathology group. Eur J Cancer 2012, (Suppl 9):120-127.
40. Benraad TH, Geurts-Moespot J, Grondahl-Hansen J, Schmitt M, Heuvel JJ, de Witte JH, Foekens JA, Leake RE, Brünner N, Sweep CG. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 Workshop. Eur J Cancer 1996, 32:1371-1381.
41. Sweep CGJ, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ. External quality assessment of trans-European multicenter antigen determination (enzyme-linked immunosorbent assay) of urokinase plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer extracts. Br J Cancer 1998, 78:1434-1441. 10.1038/bjc.1998.704, 2063209, 9836475.
42. Thomssen C, Vetter M, Schmidt M, Veyret C, Meisner C, von Minckwitz G, Martin P, Sweep CG, Paepke D, Harbeck N. ASCO-recommended prognostic factors uPA/PAI-1 in node-negative (N0) breast cancer patients (pts) compared to clinicopathological risk assessment within the NNBC 3-Europe trial NNBC-3 Trial Group. J Clin Oncol 2009, 27(Suppl):544. ASCO Annual Meeting Proceedings (Post-Meeting Edition).
43. Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 2012, 18:1515-1523. 10.1158/1078-0432.CCR-11-2206, 3307147, 22422403.
44. Duffy MJ. Do proteases play a role in cancer invasion and metastasis?. Eur J Cancer Clin Oncol 1987, 23:583-589. 10.1016/0277-5379(87)90326-9, 3308476.
45. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast cancer. Preliminary report Cancer 1988, 62:531-533.
46. Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989, 2:1049. 10.1016/S0140-6736(89)91070-2, 2572788.
47. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H. The urokinase-type plasminogen activator (u-PA) is a potent predictor of early relapse in breast cancer. Fibrinolysis 1990, 4:69-78.
48. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer. Sem Thromb Hemostasis 1991, 17:303-312.
49. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ. Urokinase plasminogen activator and prognosis in breast cancer. Lancet 1990, 335:109.
50. Spryatos F, Martin P-M, Hacene K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Le Doussal V, Tubiana-Hulin M, Brunet M. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992, 84:1266-1272. 10.1093/jnci/84.16.1266, 1640487.
51. Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, Andre J, Bobin JY. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin Breast Cancer 2008, 8:168-177. 10.3816/CBC.2008.n.018, 18621614.
52. Foekens J, Schmitt M, Pache L, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992, 52:6101-6105.
53. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinoma are associated with poor prognosis. Cancer Res 1993, 53:2513-2521.
54. Bouchet C, Spyratos F, Martin P-M, Hacène K, Gentile A, Oglobine J. Prognostic role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994, 69:398-405. 10.1038/bjc.1994.74, 1968685, 8297742.
55. Sumiyoshi K, Urano T, Takada Y, Takada A. PAI-1 and PAI-2 levels as predictors in staging malignancy in breast cancer. Fibrinolysis in Disease 1995, 26-30. CRC Press, Boca Raton, FL, Glas-Greenwalt P.
56. Ferno M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer: analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996, 32A:793-801. 10.1016/0959-8049(95)00652-4, 9081356.
57. Shiba E, Kim SJ, Taguchi T, Izukura M, Kobayashi T, Furukawa J, Yayoi E, Shin E, Takatsuka Y, Koyama H, Takai S. A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. J Cancer Res Clin Oncol 1997, 123:555-559. 10.1007/s004320050104, 9393589.
58. Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T. Cellular localisation of urokinase-type plasminogen activator, its inhibitors and their mRNA in breast cancer tissue. J Pathol 1997, 183:388-397. 10.1002/(SICI)1096-9896(199712)183:4<388::AID-PATH943>3.0.CO;2-I, 9496254.
59. Knoop A, Andreasen PA, Anderson JA, Hansen S, Laenkholm AV, Simonsen AC, Andersen J, Overgaard J, Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998, 77:932-940. 10.1038/bjc.1998.154, 2150087, 9528837.
60. Peyrat J-P, Vanlemmens L, Fournier J, Huet G, Révillion F, Bonneterre J. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancer. Clin Cancer Res 1998, 4:189-196.
61. Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S. Prognostic impact of urokinase-type plasminogen activator (uPA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998, 4:177-182.
62. Tetu B, Brisson J, Lapointe H. Prognostic significance of stromelysin 3, gelatinase A and urokinase expression in breast cancer. Human Pathol 1998, 29:979-985.
63. Eppenberger U, Kueng W, Schlaeppi J-M, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998, 16:3129-3136.
64. Kute TE, Grondahl-Hansen J, Shao S-M, Long R, Russell G, Brünner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols define a group of node-negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998, 47:9-16. 10.1023/A:1005882520982, 9493971.
65. Broet P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, Rallet A, Toulas C, Asselain B. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicenter study. Br J Cancer 1999, 80:536-545. 10.1038/sj.bjc.6690389, 2362331, 10408864.
66. Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. HER-2 and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001, 7:2448-2457.
67. Malmstrom P, Bendahl P-O, Boiesen P, Brünner N, Idvall I, Fernö M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histological grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001, 19:2010-2019.
68. Meo S, Dittadi R, Sweep CGJ, Leon A, Peloso L, Geurts-Moespot A, Grebenchtchikov N, Gion M. Prognostic value of VEGF, uPA, PAI-1 in 196 node negative breast cancers. Int J Biol Markers 2002, 17:S44.
69. Harbeck N, Dettmar C, Thomssen C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H, Schmitt M. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 1999, 80:419-426. 10.1038/sj.bjc.6690373, 2362313, 10408848.
70. Le Goff JM, Lavayssiere L, Rouesse J, Spyratos F. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks. Anticancer Res 2000, 20:2213-2218.
71. Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott EW, Fennelly JJ, O'Higgins N. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enz Protein 1996, 49:85-93.
72. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualised therapy in primary breast cancer is greatest when used in combination. J Clin Oncol 2002, 20:1000-1007. 10.1200/JCO.20.4.1000, 11844823.
73. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase plasminogen activator (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993, 24:195-208. 10.1007/BF01833260, 8435475.
74. Duffy MJ, Reilly D, McDermott EW, O'Higgins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994, 74:2276-2280. 10.1002/1097-0142(19941015)74:8<2276::AID-CNCR2820740811>3.0.CO;2-7, 7922979.
75. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase plasminogen activator: a new and independent prognostic marker in breast cancer. Cancer Res 1990, 50:6827.
76. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F, Klijn JG. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994, 12:1648-1658.
77. Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N, Duffy MJ. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 1997, 76:622-627. 10.1038/bjc.1997.435, 2228003, 9303361.
78. Billgren AM, Ritqvist LE, Johansson H, Hägerström T, Skoog L. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment with adjuvant tamoxifen. Eur J Cancer 2000, 36:1374-1380. 10.1016/S0959-8049(00)00114-3, 10899650.
79. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002, 62:4617-4622.
80. Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Foekens JA, Beex LV, Sweep CG. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res 2004, 64:659-664. 10.1158/0008-5472.CAN-03-1820, 14744782.
81. Borstnar S, Sadikov A, Mozina B, Cufer T. High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res Treat 2010, 121:615-624. 10.1007/s10549-009-0691-8, 20039121.
82. Harbeck N, Kates RE, Look MP, Foekens JA. Pooled analysis (n = 8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer. J Clin Oncol 2004, 23:523.
83. Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. Breast Cancer Res Treat 2013, 138:839-850. 10.1007/s10549-013-2496-z, 23568480.
84. Harbeck N, Sotlar K, Wuerstlein R, Doisneau-Sixou S. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat Rev 2014, 40:434-444. 10.1016/j.ctrv.2013.09.014, 24138841.
85. Gluz O, Kreipe H, Degenhardt T, Christgen M, Kates R, Liedtke C, Shak S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N. Prospective comparison of risk assessment tools in early breast cancer (recurrence score, uPA/PAI-1, central grade, and luminal subtypes): final correlation analysis from the phase III WSG-plan B trial. Cancer Res 2011, 71(24 Suppl):S4-3.
86. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
87. Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 2005, 26:281-293. 10.1159/000089260, 16254457.
88. Sturgeon CM, Duffy MJ, Stenman UK, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. Clin Chem 2008, 54:e11-79. 10.1373/clinchem.2008.105601, 19042984.
89. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24:vi7-vi23. 10.1093/annonc/mdt284, 23970019.
90. TRANSIT-Informationsseite. http://www.agoonline.de/fileadmin/downloads/leitlinien/mamma/march2012/06_2012E_Prognostic_and_Predictive_Factors.pdf
91. Thomssen C, Harbeck N, Dittmer J, Abraha-Spaeth SR, Papendick N, Paradiso A, Lisboa B, Jaenicke F, Schmitt M, Vetter M. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J Natl Cancer Inst 2009, 101:1028-1029. 10.1093/jnci/djp145, 19535782.
92. Lang DS, Heilenkötter U, Schumm W, Behrens O, Simon R, Vollmer E, Goldmann T. Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer. Breast 2013, 22:736-743. 10.1016/j.breast.2012.12.011, 23332148.
93. Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel. BMC Cancer 2011, 11:140. 10.1186/1471-2407-11-140, 3089797, 21496284.
94. Thomssen C, Kantelhardt E-J, Meisner C, Vetter M, Schmidt M, Martin P-M, Veyret C, Augustin D, Hanf V, Paepke D, Sweep FCG, Schmitt M, von Minchwitz G, Jaenicke F, Harbeck N: Analysis of the NNBC 3-Europe trial: addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. Cancer Res 2012, 72.(24 Suppl): Abstract P1-13-02.
95. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001, 19:3817-3827.
96. Degenhardt T, Gluz O, Kreipe H, Henschen S, Clemens MR, Salem M, Thomssen C, Kreipe H, Harbeck N, Nitz U. Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1. J Clin Oncol 2011, 29(Suppl):10594.
97. Goldstein LJ. Experience in phase I trials and an upcoming phase II study with upa inhibitors in metastatic breast cancer. Breast Care (Basel) 2008, 3:25-28. 10.1159/000151733, 2930999, 20824011.
98. Goldstein LJ, Oliveira CT, Heinrich B, Stemmer SM, Mala C, Selder S, Bevan P, Harbeck N. A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2013, 31(Suppl):508.
99. Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer 2013, 108:766-770. 10.1038/bjc.2013.62, 3590684, 23412098.